Abstract
Objective:
Endothelial to mesenchymal transition may represent a key link between inflammatory stress and endothelial dysfunction seen in aortic aneurysm disease. Endothelial to mesenchymal transition is regulated by interleukin-1β, and previous work has demonstrated an essential role of interleukin-1 signaling in experimental aortic aneurysm models. We hypothesize that endothelial to mesenchymal transition is present in murine aortic aneurysms, and loss of interleukin-1 signaling attenuates this process.
Methods:
Murine aortic aneurysms were created in novel CDH5-Cre lineage tracking mice by treating the intact aorta with peri-adventitial elastase. Endothelial to mesenchymal transition transcription factors as well as endothelial and mesenchymal cell markers were analyzed via immunohistochemistry and immunofluorescence (n = 10/group). To determine the role of interleukin-1 signaling, endothelial-specific interleukin-1 receptor 1 knockout and wild-type mice (n = 10/group) were treated with elastase. Additionally, C57/BL6 mice were treated with the interleukin-1 receptor 1 antagonist Anakinra (n = 7) or vehicle (n = 8).
Results:
Elastase treatment yielded greater aortic dilation compared with controls (elastase 97.0% ± 34.0%; control 5.3% ± 4.8%; P < .001). Genetic deletion of interleukin-1 receptor 1 attenuated aortic dilation (control 126.7% ± 38.7%; interleukin-1 receptor 1 knockout 35.2% ± 14.7%; P <.001), as did pharmacologic inhibition of interleukin-1 receptor 1 with Anakinra (vehicle 146.3% ± 30.1%; Anakinra 63.5% ± 23.3%; P < .001). Elastase treatment resulted in upregulation of endothelial to mesenchymal transition transcription factors (Snail, Slug, Twist, ZNF) and mesenchymal cell markers (S100, alpha smooth muscle actin) and loss of endothelial cell markers (vascular endothelial cadherin, endothelial nitric oxide synthase, von Willebrand factor). These changes were attenuated by interleukin-1 receptor 1 knockout and Anakinra treatment.
Conclusions:
Endothelial to mesenchymal transition occurs in aortic aneurysm disease and is attenuated by loss of interleukin-1 signaling. Endothelial dysfunction through endothelial to mesenchymal transition represents a new and novel pathway in understanding aortic aneurysm disease and may be a potential target for future treatment.
Keywords: aortic aneurysm, inflammation
Graphical Abstract

EndMT occurs in aortic ECs exposed to inflammatory stimuli (IL-1β).
Aortic aneurysms (AAs) are a prevalent and morbid disease with approximately 150,000 deaths due to AAs worldwide in 2020.1 It is a disease process that remains largely asymptomatic until complications occur, such as rupture and dissection, which are correlated to aortic diameter.1–3 Elective repair carries significant morbidity, and patients diagnosed with small AAs often wait to undergo intervention until the risk of rupture or dissection exceeds the risk of surgery.3–5 The mechanisms that contribute to AA progression remain poorly understood, and, as such, there is currently no standard for medical management of small AAs or for AAs in patients unable to undergo surgical intervention.6,7
Endothelial cells (ECs) display remarkable heterogeneity in their response to exogenous stimuli.8 Endothelial to mesenchymal transition (EndMT) is the process through which ECs lose endothelial characteristics and acquire mesenchymal phenotypes, thereby leading to a loss of normal EC function in maintaining vascular homeostasis.9 This process has been demonstrated in various pathological states, including tissue fibrosis and atherosclerosis, and has emerged as a key driver of vascular inflammation.10–12 Vascular inflammation is thought to play a fundamental role in the pathogenesis of AAs, and EndMT may represent a key link between inflammatory stress and endothelial dysfunction seen in AA disease.9 However, there have been no studies examining the role of EndMT in AAs.
Interleukin-1β (IL-1β) has been implicated as a main driving factor of EndMT.13 IL-1 is a primary effector of the inflammatory cascade and our previous work has demonstrated an essential role of IL-1β in experimental AA models as well as AA attenuation through pharmacological inhibition of the IL-1 receptor (IL-1R).14,15 Although the exact mechanism of these effects is unknown, the extent of vascular inflammation and, as a result, EndMT may be contributing factors. We hypothesized that EndMT is present in AAs and loss of IL-1 signaling attenuates this process. The purpose of this study was to further evaluate the role of EndMT in AA pathogenesis with the goal of identifying a new and novel therapeutic target for the treatment of AAs.
MATERIAL AND METHODS
All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Michigan, protocol PRO00010144 (approved April 27, 2021). With written informed consent, human tissue was collected and used in accordance with the Human Subjects Review Committee at the University of Virginia, Institutional Review Board protocol 12178 (approved July 16, 2008).
Murine Elastase AA Model
Murine abdominal AA induction was performed using a periadventitial elastase application as previously described.16 Novel CDH5-Cre (VEC-Cre) eYFP +/+ endothelial specific lineage tracking mice were generated using CDH5-Cre and eYFP mice (Jax Laboratory) bred on a C57BL/6 background.17 Briefly, both male and female CDH5-Cre eYFP +/+ mice between 8 and 10 weeks of age underwent midline laparotomy and abdominal aortic exposure. The abdominal aorta (n = 5/sex/group) was treated with full-strength elastase or saline control. Optimal elastase dose and duration were determined by a dose-response curve conducted before these experiments by each individual surgeon to reliably produce 110% aortic dilation in control mice. Infrarenal abdominal aortas from both groups were harvested 14 days postoperatively. At the time of harvest, the abdominal aorta was exposed in a similar fashion and the maximum aortic diameter was measured using video micrometery. A portion of the aorta that was not exposed to elastase (internal control segment) was measured and used as a control segment for diameter comparison.
Generation of Endothelial Specific Interleukin-1 Receptor Genetic Deletion Lineage Tracing Mice
To define the role of endothelial IL-1 signaling in EndMT, CDH5-Cre eYFP +/+ mice were bred with IL-1R1 knockout (KO) (flx/flx) mice to generate CDH5-Cre IL-1R1 flx/flx eYFP lineage tracing mice. IL-1R1 flx/flx mice were provided by E. Pinteaux.18 CDH5-Cre IL-1R1 wt/wt eYFP +/+ (n = 5/sex; wt/wt) and CDH5-Cre IL-1R1 flx/flx eYFP +/+ (n = 5/sex; flx/flx) underwent AA induction as described previously and were harvested on postoperative day 14.
Pharmacologic Inhibition of Interleukin-1 Receptor Using Anakinra
To test the potential clinical application of our results, we examined the role of pharmacologic antagonism of IL-1R1 using a commercially available IL-1R1 antagonist (anakinra; Biovitrum). As IL-1R1 KO demonstrated no sex-based difference in EndMT, C57BL/6 WT male mice underwent initial AA induction and were given vehicle (saline; n = 8) or anakinra (100 mg/kg per dose; n = 7) by intraperitoneal injection beginning postoperative day 14 and continuing daily until day 28. Aortas were harvested on day 28.
Histology
Murine aortas were harvested after inferior vena cava puncture and hemorrhagic shock. The collected aortas were flushed with 0.9% saline and immersed in 4% paraformaldehyde at 4 °C overnight. After paraffin embedding, blocks were sectioned every 5 μm. Verhoeff-Van Gieson (VVG) for elastin layers and immunohistochemical staining were completed. After microwave retrieval, antibodies were bound and detected using VectaStain Elite kit (Vector Laboratories Inc). Antibodies for immunohistochemical staining were anti-Snail (1:200; Abcam), anti-Slug (1:200; Abcam), anti-Twist (1:200; Invitrogen), anti-ZNF281 (1:200; Abcam), anti-α smooth muscle actin (αSMa, 1:1000; Abcam), anti-S100A4 (1:100; Cell Signaling Technology), anti-vascular endothelial cadherin (VE-cadherin, 1:200; Abcam), anti-endothelial nitric oxide synthase (eNOS, 1:100; Abcam), and anti-Von Willebrand factor (VWF, 1:100; Abcam). Enzymatic color development was completed using diaminobenzidine (Thermo Fisher Scientific). Appropriate controls verified staining procedures and images were acquired using Keyence BZ-X800 Viewer software with a 10× objective on a Keyence BZ-X810 (Keyence Corporation). Histology was digitally analyzed using QuPath software.19 Vector gated image quantification of the positive signal within the region of interest was calculated and relative proportions of positive signals were compared between groups.
Samples were also evaluated using immunofluorescence and confocal microscopy. Samples were stained for eYFP (1:100, Abcam), αSMa (1:1000, Abcam), VE-cadherin (1:200, Abcam), VWF (1:1000, Abcam), and nuclei with DAPI (1:10,000; Invitrogen). Images were acquired using a Nikon A1si confocal microscope with a 60× objective (Nikon Instruments). QuPath multiplex analysis was used to analyze the obtained images. Cell detection was carried out based on DAPI fluorescent signaling. Phenotyping of the cells was then performed using simple thresholding of a single measurement to classify each fluorescent biomarker applied sequentially to the previously detected cells. Percentage of cells with the phenotype of interest was determined on the basis of the number of cells that expressed the lineage marker eYFP.
Human Aneurysm Analysis
Normal aortic tissue was obtained from patients undergoing coronary artery bypass grafting (n = 11; male = 6, female = 5). Aneurysmal aortas (n = 12 ascending thoracic aortic aneurysm [aTAA]; n = 13 descending thoracic aortic aneurysm [dTAA]; n = 13 abdominal aortic aneurysm [AAA]) were taken from patients undergoing elective open AA repair. Aortas with known collagen vascular disease, genetic aortopahy, or bicuspid aortic valve were excluded.
Aortic tissue specimens were explanted, placed in 4% paraformaldehyde overnight, and embedded in paraffin. Immunohistochemistry was performed and digitally analyzed, as previously described. Antibodies for immunohistochemical staining were anti-Snail (1:300, Abcam), anti-Slug (1:600, Abcam), anti-S100A4 (1:500, Cell Signaling Technologies), and anti-VWF (1:1500, Abcam).
Statistical Method
Maximal aortic dilation (%) was calculated as [maximal aortic diameter − internal control segment] ÷ internal control segment × 100%. Values are reported as mean SD. Histology was digitally analyzed using positive cell detection (immunohistochemistry), percentage positive pixels (VVG), and multiplexed analysis (immunofluorescence).19,20 Values are reported as median (interquartile range). Differences between groups was compared using Mann–Whitney U test with significance determined at α = 0.05. Statistical analysis and graphical presentations were performed using Prism 9 software (GraphPad Software).
RESULTS
Endothelial to Mesenchymal Transition Is Present in Experimental Aortic Aneurysm Model
Aortic dilation increased after elastase exposure compared with saline-exposed controls (elastase: 97.0% ± 34.0%; control: 5.3% ± 4.8%; P <.001; Figure 1, A). There was no difference in aortic dilation after elastase exposure according to sex (male: 105.9% ± 40.5%; female: 88.0% ± 27.6%; P = .548). VVG staining demonstrated decreased elastin fibers in elastase exposed aortas compared with controls (elastase: 6.4 [1.8–18.0] percent positive pixels [PPP]; control: 19.4 [15.4–25.4] PPP; P = .015; Figure 1, B and C).
FIGURE 1.

Murine models of AA demonstrate increased elastin degradation, increased EndMT transcription factor and mesenchymal cell marker staining, and decreased EC marker staining after topical elastase. A, Abdominal aortic dilation in CDH5-Cre (VEC-Cre) lineage tracking mice exposed to elastase was significantly greater than CDH5-Cre (VEC-Cre) mice exposed to saline after 14 days (P <.001). B, By immunohistochemistry, representative aortic cross-sections demonstrated increased staining of the EndMT transcription factor Twist and the mesenchymal marker S100 in CDH5-Cre elastase treated mice. Additionally, the samples demonstrated decreased staining of the endothelial marker VE-cadherin and elastin in CDH5-Cre elastase-treated mice. Scale bar, 100 μM. C, Histologic analysis using positive cell detection demonstrated significant increase in EndMT transcription factors (Snail [P <.001], Slug [P <.001], Twist [P <.001], ZNF281 [P <.001]) and mesenchymal cell markers (S100 [P <.001], ⍺SMA [P <.001]) in CDH5-Cre elastase-treated mice. Conversely, EC markers (VE-cadherin [P <.001], eNOS [P <.001], VWF [P <.001]) were preserved in CDH5-Cre saline-treated mice. Percent positive pixel detection demonstrated decreased elastin in CDH5-Cre elastase-treated mice (P = .015). *For all graphs, a horizontal line represents the median of the respective data. AAA, Abdominal aortic aneurysm; αSMa, alpha smooth muscle actin; eNOS, endothelial nitric oxide synthase; VWF, von Willebrand factor.
By immunohistochemistry, elastase-exposed aortas demonstrated greater staining of the EndMT transcription factors Snail (elastase: 53.5 [39.9–67.1] percent cell positivity [%]; control: 8.4 [1.5–20.5]%; P<.001), Slug (elastase: 57.9 [47.0–63.4]%; control: 13.8 [9.72–16.1]%; P <.001), Twist (elastase: 74.6 [56.1–81.3]%; control: 29.5 [21.2–35.7]%; P < .001), and ZNF281 (elastase: 59.8 [42.2–63.8]%; control: 3.4 [2.5–13.0]%; P <.001) (Figure 1, B and C). Likewise, elastase exposure resulted in decreased staining of the EC markers VE-cadherin (elastase: 9.8 [5.9–14.2]%; control: 29.7 [26.5–43.2]%; P < .001), eNOS (elastase: 1.0 [0.0–6.0]%; control: 24.2 [17.2–28.6]%; P <.001), and VWF (elastase: 6.5 [4.3–15.6]%; control: 67.4 [67.0–74.1%]; P <.001) and increased staining of the mesenchymal cell markers αSMA (elastase: 68.8 [65.8–87.0]%; control: 25.0 [23.4–26.3]%; P <.001) and S100A4 (elastase: 52.8 [45.5–63.4]%; control: 5.8 [3.6–9.8]%; P <.001) (Figure 1, B and C).
Lineage Tracing Demonstrates Transition of Endothelial Cells to Mesenchymal Cells in Experimental Aortic Aneurysm Model
To better delineate ECs undergoing mesenchymal transition, novel CDH5-Cre (VEC-Cre) endothelial-specific lineage tracking mice were used. This allowed for the constitutive expression of eYFP in endothelial-originating cells. Cells were considered Transitioned if they expressed eYFP and the mesenchymal cell marker αSMA. Likewise, cells were considered Transitioning if they expressed eYFP, the mesenchymal cell marker αSMA, and the EC marker VWF or VE-cadherin. Two EC markers were used to replicate and validate results.
By using the EC marker VWF, CDH5-Cre mice exposed to elastase demonstrated a greater proportion of Transitioned (elastase: 57.2 [41.6–76.0] percentage of cells [%]; control: 8.7 [2.6–18.0]%; P = .001) and Transitioning cells (elastase: 30.4 [23.2–33.5]%; control: 8.3 [2.2–18.8]%; P = .002) compared with saline-exposed controls (Figure 2). Similar results were seen using the EC marker VE-cadherin in which CDH5-Cre mice exposed to elastase demonstrated a greater proportion of Transitioned (elastase: 38.1 [17.1–62.6]%; control: 0.1 [0.0–1.1]%; P <.001) and Transitioning cells (elastase: 25.0 [9.7–38.6]%; control: 0.2 [0.0–6.3]%; P = .01) compared with saline-exposed controls (Figure 2).
FIGURE 2.

Endothelial lineage tracing demonstrates increased endothelial-originating cells with loss of EC markers and expression of mesenchymal cell markers (Transitioned) or co-expression of endothelial and mesenchymal cell markers (Transitioning) after topical elastase. A, Immunofluorescence and confocal microscopy performed on CDH5-Cre (VEC-Cre) eYFP +/+ endothelial specific lineage tracking mice. Cell nuclei (DAPI) are shown in blue, CDH5-Cre linage marker in purple, VWF in green, and αSMA in red. Merged image demonstrates αSMA colocalization with VWF and endothelial lineage marker in CDH5-Cre elastase-treated mice but not in CDH5-Cre saline-treated mice. B, Histologic analysis using multiplexed analysis demonstrated significant increase in endothelial to mesenchymal Transitioned and Transitioning cells using the EC markers VWF (Transitioned, P = .001; Transitioning, P = .002) and VE-cadherin (Transitioned, P<.001; Transitioning, P = .010) in CDH5-Cre elastase-treated mice. For all graphs, a horizontal line represents the median of the respective data. AAA, Abdominal aortic aneurysm; VE-Cadherin, vascular endothelial cadherin; H&E, hematoxylin–eosin; VWF, von Willebrand factor.
Interleukin-1 Signaling Is Critical for Endothelial to Mesenchymal Transition in Aortic Aneurysm Formation
With IL-1β signaling shown to be critical in experimental AAs and a main driving factor of EndMT, we tested the hypothesis that IL-1β is required for EndMT and AA formation by performing elastase application on endothelial IL-1R1 KO mice (Flx/Flx).13,14 Genetic deletion of IL-1R1 demonstrated significant protection against aortic dilation with more than 90% absolute reduction in maximal aortic dilation compared with wild-type controls (Wt/Wt) (Wt/Wt: 126.7% ± 38.7%; Flx/Flx: 35.2% ± 14.7%; P <.001; Figure 3, A). There was no difference in aortic dilation in IL-1R1 KO mice (Flx/Flx) by sex (male: 38.1% ± 14.8%; female: 30.8% ± 15.5%; P = .762). Protection from elastase injury in mice with IL-1R1 deletion was further demonstrated with greater elastin fibers present in IL-1R1 KO mice (Flx/Flx) compared with controls (Wt/Wt: 2.0 [0.9–2.9] PPP; Flx/Flx: 8.8 [3.5–11.6] PPP; P = .025; Figure 3, B and C).
FIGURE 3.

IL-1R1 KO mice demonstrate decreased elastin degradation, decreased EndMT transcription factor and mesenchymal cell marker staining, and increased EC marker staining after topical elastase. A, Abdominal aortic dilation in CDH5 IL-1R KO (flx/flx) mice was significantly less than CDH5 IL-1R wild-type (wt/wt) mice 14 days after exposure to elastase (P <.0001). B, By immunohistochemistry, representative aortic cross-sections demonstrated increased staining of the EndMT transcription factor Snail and the mesenchymal marker ⍺SMA in CDH5 IL-1R wild-type (wt/wt) mice. Additionally, the samples demonstrated decreased staining of the endothelial marker VE-cadherin and elastin in CDH5 IL-1R KO (wt/wt) mice. Scale bar, 100 μM. C, Histologic analysis using positive cell detection demonstrated significant increase in EndMT transcription factors (Snail [P = .006], Slug [P = .004], Twist [P <.001], ZNF281 [P <.001]) and mesenchymal cell markers (S100 [P = .036], ⍺SMA [P = .019]) in CDH5 IL-1R wild-type (wt/wt) mice. Conversely, EC markers (VE-cadherin [P = .012], eNOS [P = .005], and VWF [P<.001]) were preserved in CDH5 IL-1R KO (flx/flx) mice. Percent positive pixel detection demonstrated decreased elastin in CDH5 IL-1R wild-type (wt/wt) mice (P = .025). *For all graphs, a horizontal line represents the median of the respective data. VVG, Verhoeff-Van Gieson; αSMa, alpha smooth muscle actin; eNOS, endothelial nitric oxide synthase; VWF, von Willebrand factor.
Genetic deletion of endothelial IL-1R1 resulted in decreased staining of the EndMT transcription factors Snail (Wt/Wt: 65.2 [46.6–72.3]%; Flx/Flx: 32.5 [12.1–44.4]%; P = .006), Slug (Wt/Wt: 50.6 [39.8–58.2]%; Flx/Flx: 25.3 [9.3–36.0]%; P = .004), Twist (Wt/Wt: 82.0 [79.1–87.5]%; Flx/Flx: 59.4 [39.7–65.4]%; P < .001), and ZNF281 (Wt/Wt: 55.2 [43.3–89.2]%; Flx/Flx: 24.6 [6.5–36.2]%; P < .001) after elastase exposure (Figure 3, B and C). Likewise, IL-R1 deletion resulted in greater staining of the EC markers VE-cadherin (Wt/Wt: 32.9 [28.3–40.0]%; Flx/Flx: 54.6 [37.5–64.6]%; P = .012), eNOS (Wt/Wt: 11.8 [0.0–20.0]%; Flx/Flx: 32.8 [19.0–46.7]%; P = .005), and VWF (Wt/Wt: 10.1 [2.5–18.0]%; Flx/Flx: 86.4 [81.1–88.8]%; P < .001) and decreased staining of the mesenchymal cell markers αSMA (Wt/Wt: 61.3 [44.2–74.4]%; Flx/Flx: 38.3 [24.5–53.9]%; P = .019) and S100A4 (Wt/Wt: 47.0 [41.2–54.3]%; Flx/Flx: 31.9 [16.1–48.1]%; P = .036) after elastase exposure (Figure 3, B and C).
Using an endothelial specific lineage tracing murine model (CDH5-Cre IL-1R1 flx/flx eYFP), genetic deletion of IL-1R1 also demonstrated decreased endothelial to mesenchymal phenotype transition after elastase exposure. As previously described, cells were considered Transitioned if they expressed eYFP and the mesenchymal cell marker αSMA or Transitioning if they expressed eYFP, the mesenchymal cell marker αSMA, and the EC marker VWF or VE-cadherin. By using the EC marker VWF, IL-1R1 KO mice (Flx/Flx) demonstrated decreased Transitioned (Wt/Wt: 29.9 [20.5–38.6]%; Flx/Flx: 8.0 [4.9–11.4]%; P <.001) and Transitioning cells (Wt/Wt: 50.1 [24.7–56.9]%; Flx/Flx: 12.2 [5.5–29.6]%; P = .030) compared with wild-type controls (Wt/Wt). Similar results were seen using the EC marker VE-cadherin in which IL-1R1 KO mice (Flx/Flx) demonstrated decreased Transitioned (Wt/Wt: 38.4 [25.4–48.0]%; Flx/Flx: 8.7 [2.6–19.8]%; P = .006) and Transitioning cells (Wt/Wt: 21.3 [13.2–31.0]%; Flx/Flx: 8.4 [0.0–14.2]%; P = .020) compared with wild-type controls (Wt/Wt) (Figure 4).
FIGURE 4.

IL-1R1 KO mice demonstrate decreased endothelial-originating cells with loss of EC markers and expression of mesenchymal cell markers (Transitioned) or co-expression of endothelial and mesenchymal cell markers (Transitioning) after topical elastase. A, Immunofluorescence and confocal microscopy performed on CDH5 IL-1R1 KO (flx/flx) and wild-type (wt/wt) lineage tracing mice. Cell nuclei (DAPI) are shown in blue, CDH5-Cre linage marker in purple, VWF in green, and αSMA in red. Merged image demonstrates αSMA colocalization with VWF and endothelial lineage marker in CDH5 IL-1R wild-type (wt/wt) mice but not in CDH5 IL-1R1 KO (flx/flx) mice. B, Histologic analysis using multiplexed analysis demonstrated significant decrease in endothelial to mesenchymal Transitioned and Transitioning cells using the EC markers VWF (Transitioned, P < .001; Transitioning, P = .030) and VE-cadherin (Transitioned, P = .006; Transitioning, P = .020) in CDH5 IL-1R1 KO (flx/flx) mice. For all graphs, a horizontal line represents the median of the respective data. VE-Cadherin, Vascular endothelial cadherin; αSMa, alpha smooth muscle actin; H&E, hematoxylin–eosin; VWF, von Willebrand factor.
Pharmacologic Antagonism Attenuates Endothelial to Mesenchymal Transition in Aortic Aneurysm Formation
Given that genetic deletion of endothelial IL-1R1 attenuated EndMT and aortic dilation, we hypothesized that pharmacological inhibition of the IL-1R using Anakinra (a potent IL-1R antagonist) would also result in attenuation of EndMT and aortic dilation.21 To study the translational applications of our hypothesis, mice underwent elastase exposure and were treated with Anakinra or saline (vehicle) beginning postoperative day 14 after an AA had already formed. Treatment with Anakinra at 100 mg/kg/d reduced absolute aortic dilation by more than 80% compared with controls treated with vehicle (vehicle: 146.3% ± 30.1%; Anakinra: 63.5% ± 23.3%; P <.001; Figure 5, A). Mice treated with Anakinra demonstrated greater elastin preservation compared with vehicle (vehicle: 7.1 [4.0–15.9] PPP; Anakinra: 15.6 [12.9–27.4] PPP; P = .038; Figure 5, B and C).
FIGURE 5.

Murine models of AA demonstrate decreased elastin degradation, decreased EndMT transcription factor and mesenchymal cell marker staining, and increased EC marker staining after treatment with Anakinra. A, Abdominal aortic dilation in C57BL/6 WT mice who received Anakinra 14 days after elastase exposure was less than WT mice who received Vehicle (saline) (P<.001). B, By immunohistochemistry, representative aortic cross-sections demonstrated decreased staining of the EndMT transcription factor ZNF and the mesenchymal marker S100A4 in WTAnakinra-treated mice. Additionally, the samples demonstrated increased staining of the endothelial marker eNOS and elastin in WT Anakinra-treated mice. Scale bar, 100 μM. C, Histologic analysis using positive cell detection demonstrated significant decrease in EndMT transcription factors (Snail [P = .006], Slug [P = .036], Twist [P = .027], ZNF281 [P = .047]) and mesenchymal cell markers (S100A4 [P = .002], ⍺SMA [P = .006]) in WTAnakinra-treated mice. Additionally, EC markers (VE-cadherin [P = .003], eNOS [P = .040], VWF [P <.001]) were preserved in WT Anakinra-treated mice. Percent positive pixel detection demonstrated decreased elastin in WT vehicle-treated mice (P = .038). *For all graphs, a horizontal line represents the median of the respective data. VVG, Verhoeff-Van Gieson; αSMa, alpha smooth muscle actin; VE-Cadherin, vascular endothelial cadherin; eNOS, endothelial nitric oxide synthase; VWF, von Willebrand factor.
Anakinra-treated mice demonstrated decreased staining of the EndMT transcription factors Snail (vehicle: 51.5 [43.9–64.8]%; Anakinra: 9.2 [2.8–18.3]%; P = .006), Slug (vehicle: 24.3 [23.6–32.0]%; Anakinra: 2.8 [0.3–6.1]%; P = .036), Twist (vehicle: 47.5 [8.6–63.1]%; Anakinra: 6.6 [0.9–17.7]%; P = .027), and ZNF281 (vehicle: 37.7 [4.5–65.0]%; Anakinra: 6.4 [3.7–14.9]%; P = .047) via immunohistochemistry staining. Additionally, they demonstrated preserved staining of the EC markers VE-cadherin (vehicle: 1.7 [0.6–7.7]%; Anakinra: 29.9 [13.0–52.9]%; P = .003), eNOS (vehicle: 1.5 [0.1–3.2]%; Anakinra: 6.2 [2.5–106]%; P = .040), and VWF (vehicle: 1.4 [0.3–4.5]%; Anakinra: 31.1 [19.1–42.5%]; P <.001) and decreased staining of the mesenchymal cell markers αSMA (vehicle: 48.7 [32.1–59.3]%; Anakinra: 21.4 [17.8–35.6]%; P = .006) and S100A4 (vehicle: 22.5 [12.5–30.7]%; Anakinra: 2.51 [0.9–10.4]%; P = .002).
Endothelial to Mesenchymal Transition in Present in Human Aortic Aneurysm
To confirm whether these findings apply to human AA disease, immunohistochemistry of human aneurysmal and control aortas was performed. The cell markers used included the EndMT transcription factors Snail and Slug, mesenchymal cell marker S100A4, and EC marker VWF. Aneurysmal tissue, regardless of region, demonstrated greater staining of the EndMT transcription factors Snail (control: 1.1 [0.6–1.9] Percent Cell Positivity [%]; aTAA: 46.2 [27.0–66.3]%, P <.001; dTAA: 34.8 [12.9–61.2]%, P<.001; AAA: 12.6 [4.2–43.2]%, P = .04) and Slug (control: 5.6 [1.6–8.0]%; aTAA: 13.8 [11.4–26.7]%, P = .02; dTAA: 12.7 [10.3–31.8]%, P = .02; AAA: 26.8 [13.5–71.0]%, P = .0001) compared with controls. AAA tissue also demonstrated decreased staining of the EC marker VWF (control: 55.2 [27.2–74.1]%; AAA: 13.3 [5.3–26.9]%; P = .01) and increased staining of the mesenchymal cell marker S100 (control: 8.3 [3.4–18.1]%; AAA: 76.4 [37.8–95.2]%; P<.001) compared with controls (Figure 6). However, aTAA and dTAA tissue demonstrated no difference in staining for VWF (control: 55.2 [27.2–74.1]%; aTAA: 23.3 [4.9–42.6]%; P = .16; dTAA: 29.9 [17.5–43.2]%; P > .9) and S100 (control: 8.3 [3.4–18.1]%; aTAA: 21.3 [10.4–25.3]%; P > .9; dTAA: 16.8 [6.5–23.0]%; P >.9) compared with controls (Figure 6).
FIGURE 6.

Human aneurysms demonstrate increased EndMT transcription factor and differences in mesenchymal cell marker and EC markers staining. A, By immunohistochemistry, human AA cross-sections, regardless of region, demonstrated increased staining of the EndMT transcription factors Snail and Slug. AAA demonstrated increased staining of the mesenchymal cell marker S100 and decreased staining of the EC marker VWF, whereas aTAA and dTAA tissue demonstrated little difference in staining for S100 and VWF compared with controls. Scale bar, 100 μM. B, Histologic analysis using positive cell detection demonstrated significant increase of the EndMT transcription factors Snail (aTAA: P <.001; dTAA: P <.001; AAA: P = .04) and Slug (aTAA: P = .02; dTAA: P = .02; AAA: 26.8 P = .0001) compared with controls. AAA tissue also demonstrated decreased staining of the EC marker VWF (P = .01) and increased staining of the mesenchymal cell marker S100 (P <.001) compared with controls. However, aTAA and dTAA tissue demonstrated no difference in staining for VWF (aTAA: P = .16; dTAA: P>.9) and S100 (aTAA: P>.9; dTAA: P>.9) compared with controls. VWF, Von Willebrand factor.
DISCUSSION
The role of ECs in the pathogenesis of AA formation has been largely understudied. In this study, we demonstrated the finding that EndMT occurs in both murine and human AAAs and that IL-1 signaling plays a role in this process. Genetic disruption of IL-1 signaling through IL-1R1 deletion significantly attenuated murine AA formation, and treatment with the IL-1R1 inhibitor, Anakinra, in established AAs similarly attenuated progression of aortic dilation. Of note, markers of EndMT were decreased in both murine models of IL-1 signaling inhibition compared with controls. These findings suggest that endothelial dysfunction during inflammation may be a factor in the formation and progression of AA disease and that IL-1 signaling may play an important role in promoting endothelial dysfunction through activation of EndMT in AAs. As such, the role of endothelial dysfunction and EndMT in AA disease offers a new and novel area of study as we further our understanding of AA disease and may help in the identification of new targets for medical management.
Until now, there have been no studies directly examining the role of EndMT in AA disease. Our results demonstrate that dynamic phenotypic switching of ECs to mesenchymal cells occurs in the setting of inflammation during AA formation. Using a novel linage tracing murine model, we demonstrated the remarkable heterogeneity vascular ECs are able to undergo in response to exogenous inflammatory stimuli by identifying and characterizing Transitioned and Transitioning ECs.9 This phenotypic switch is driven by the expression of several, well-established EndMT transcription factors including the zinc-finger binding transcription factors Snail-1, Snail-2 (also known as Slug) and the transcription factor Twist.22,23 As a result, ECs loose expression of characteristic markers such as VWF, eNOS, and VE-cadherin, which are critical to maintaining endothelial junctions, polarity, and vascular homeostasis.13,24,25 In return, they gain expression of mesenchymal cell markers including S100A4 and αSMA and demonstrate alterations in cytoarchitecture, cell shape, and motility.25,26 These changes ultimately result in EC dysfunction and have been demonstrated to contribute to diseases such as organ fibrosis and atherosclerosis.12,24 In this study, genetic and pharmacologic inhibition of IL-1 were associated with significant reduction in both aortic dilation and EndMT suggesting that EndMT may represent a key link in the complex interactions between inflammation and endothelial dysfunction.9
EndMT is driven by inflammation with both IL-1β and transforming growth factor beta (TGF-β) being implicated as 2 critical regulating factors.13 Our results indicate that IL-1β is necessary for EndMT in experimental AAs with genetic deletion of IL-1R1 and pharmacologic inhibition of the IL-1R1 with Anakinra demonstrating decreased EndMT. IL-1β is considered to be an important regulator of inflammation and has been demonstrated to play a key role in AA disease.21,27,28 Previous murine models of AAs and human AAs have demonstrated increased IL-1β mRNA and protein levels.14 Tissue damage caused by external stimuli triggers the activation and release of IL-1, making it one of the earliest activated proinflammatory cytokines after injury.13 However, sustained IL-1 signaling has been implicated in late phases of tissue repair, remodeling, and scarring.29–31 The presence of IL-1 throughout the process of inflammation makes it an interesting target for studying AA disease and potential treatment.
Previous studies using human umbilical vein ECs have demonstrated that IL-1β and TGF-β synergistically induce EndMT.13 Within this interaction, TGF-β may be responsible for sustaining EndMT, whereas IL-1β is needed for efficient EndMT induction.13 This early role of IL-1β was demonstrated previously by our laboratory with the greatest increase of IL-1β gene expression and protein occurring early in AA formation before any apparent aortic dilation.14 This finding may have important clinical applications in the development of prevention versus treatment strategies for AA disease. Additional studies have demonstrated that after genetic deletion of TGF-β, IL-1β is increasingly activated as a danger signal and induces a robust innate immune response ultimately resulting in aortic wall degradation and dilation.32 Any future studies evaluating TGF-β in AA disease will need to take into consideration the role of IL-1 signaling and the interactions these 2 signaling molecules have with one another.
There is a tremendous need for medical therapy to treat patients with AA disease. In the current treatment paradigm (observation of aneurysm progression followed by surgical intervention), patients with AA disease under observation or who are poor surgical candidates would benefit greatly from medical therapy to reduce AA size or slow AA progression. Anakinra is a recombinant human IL-1R1 antagonist and was the first drug with selective IL-1R1 antagonism to receive approval from the US Food and Drug Administration. It is able to prevent the activity of both IL-1α and IL-1β and has been shown to have widespread benefit in many autoinflammatory conditions.21,33 Previous studies have demonstrated attenuated AA formation with Anakinra treatment initiated at the time of injury or shortly thereafter.14 However, to make the findings of our study more clinically translatable, delayed administration of Anakinra was used. Our results replicate previous findings that demonstrate that mice who receive Anakinra at a dose of 100 mg/kg/d have attenuated AA formation and, due to its delayed administration, further demonstrate the continued role of IL-1 signaling in AA progression.14,34 Additionally, Anakinra treatment demonstrated a similar effect on EndMT as genetic IL-1R1 deletion. This further affirms the role of IL-1 signaling in AA disease and may begin to explain the underlying pathways through which IL-1 affects AA formation and progression.
In our murine experiments, we used an abdominal AA model to evaluate EndMT in AA disease. However, we recognize that aneurysmal disease of the thoracic (TAA) and abdominal aorta represents 2 distinct disease processes with several important clinical, anatomic, and cellular differences.35 The thoracic and abdominal aorta arise from distinct embryologic cell lines and demonstrate differential responses to cytokine signaling during embryogenesis.36,37 Such differences in cytokine response may continue throughout a patient’s lifetime and result in differences in EndMT. This may help explain our finding of increased Snail and Slug signaling within aTAA, dTAA, and AAA tissue compared with controls but no difference in S100 and VWF staining in aTAA and dTAA compared with controls. Despite increased expression of EndMT transcription factors, EndMT changes appeared to be attenuated in TAA. This finding highlights the important need for further studies evaluating EndMT in TAA disease. Preliminary studies evaluating ascending TAA (aTAA) have demonstrated EndMT like changes in patients with bicuspid aortic valves.38,39 Additionally, studies evaluating EndMT specifically in descending TAA (dTAA) models are ongoing within our laboratory using a murine dTAA model previously developed.15
Study Limitations
There are several limitations to the present study that need to be noted. Although our experimental findings are limited to a surgical model of AA disease, the fusiform aneurysms formed by peri-adventitial elastase application have been demonstrated to closely model human AA disease.16 However, as aortic dissection and rupture represent clinically significant consequences of AA disease, further studies evaluating the extent of EndMT in novel models designed to mimic these changes are needed. Additionally, our experimental findings within this study are limited to histological analysis. Further studies evaluating protein expression and relevant transcripts are also warranted and currently ongoing within our laboratory.
Our murine models received Anakinra treatment at a dose of 100 mg/kg/d, which greatly exceeds the dosage approved for patient use. The excess Anakinra required to demonstrate an effect is not unique to this study and has been similarly shown by other groups evaluating Anakinra in murine models.14,34 Additionally, only male murine models received Anakinra treatment. To completely evaluate for sex-based differences in AA disease, additional studies using female murine models treated with Anakinra are warranted. Although the results of this study show an association between EndMT mediators, aneurysms size, and EndMT changes, more definitive experiments using genetic and pharmacologic inhibitors of the studied EndMT mediators are needed to further delineate their relationship.
CONCLUSIONS
Experimental murine AA models demonstrate distinct EndMT during aneurysm formation with differential expression of well-established EndMT transcription factors, EC markers, and mesenchymal cell markers. This finding has never been demonstrated to occur in aortic aneurysmal disease and expands our understanding of the role of ECs in AAs. Moreover, genetic and pharmacologic inhibition of IL-1 confers protection from experimental AA and attenuates EndMT. Our data suggest that the resulting endothelial dysfunction through EndMT may be a contributor to the pathophysiology of AA disease and may open the door to new and novel targets for the treatment of AA disease.
PERSPECTIVE.
This study is the first to demonstrate the role of EndMT in AA disease using a murine AAA model. This process is mediated through the IL-1 pathway, and genetic and pharmacologic inhibition of IL-1R1 attenuated aortic dilation and EndMT in mice. These findings offer new understanding and propose new areas of research for AAs.
Acknowledgments
This work was supported by American Heart Association Scientist Development Grant 14SDG18730000 (M.S.) and R01 HL126668 (G.A.) grants. This project was supported by Grant Number T32-HL007853 from the National Heart, Lung, and Blood Institute (J.K.M., PI: David J. Pinksy, MD). The content is solely the responsibility of the authors and does not necessarily represent the views of the National Heart, Lung, and Blood Institute.
University of Michigan Institutional Animal Care & Use Committee Approval: University of Michigan PRO00010144 (approved April 27, 2021). University of Virginia Institutional Review Board protocol 12178 (July 16, 2008). Human tissue was collected as part of this protocol with patients providing written informed consent.
The authors thank Jolian Dahl and Ian Cook Armstrong for their knowledge and technical expertise.
Abbreviations and Acronyms
- AA
aortic aneurysm
- AAA
abdominal aortic aneurysm
- αSMa
alpha smooth muscle actin
- aTAA
ascending thoracic aortic aneurysm
- dTAA
descending thoracic aortic aneurysm
- EC
endothelial cell
- EndMT
endothelial to mesenchymal transition
- eNOS
endothelial nitric oxide synthase
- IL-1
interleukin 1
- IL-1R
interleukin 1 receptor
- PPP
percent positive pixels
- TGF-β
transforming growth factor beta
- VE-cadherin
vascular endothelial cadherin
- VVG
Verhoeff-Van Gieson
- VWF
von Willebrand factor
Footnotes
Conflict of Interest Statement
G.A. reports consulting fees from Edwards, Medtronic, Abbott, Gore, Arthrex, Anteris, J&J, and Philips. All other authors reported no conflicts of interest.
The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
CENTRAL MESSAGE
EndMT occurs in a murine AA model and is attenuated through genetic and pharmacologic IL-1R1 inhibition.
References
- 1.Tsao CW, Aday AW, Almarzooq ZI, Beaton AZ, Bittencourt MS, Boehme AK, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145:E153–639. 10.1161/CIR.0000000000001052 [DOI] [PubMed] [Google Scholar]
- 2.Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73:17–27; discussion 27–8. [DOI] [PubMed] [Google Scholar]
- 3.Pape LA, Tsai TT, Isselbacher EM, Oh JK, O’Gara PT, Evangelista A, et al. Aortic diameter ≥5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation. 2007;116:1120–7. 10.1161/CIRCULATIONAHA.107.702720 [DOI] [PubMed] [Google Scholar]
- 4.Salmon M NADPH oxidases in aortic aneurysms. Antioxidants. 2022;11:1830. 10.3390/antiox11091830 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Karthikesalingam A, Holt PJ, Vidal-Diez A, Ozdemir BA, Poloniecki JD, Hinchliffe RJ, et al. Mortality from ruptured abdominal aortic aneurysms: clinical lessons from a comparison of outcomes in England and the USA. Lancet. 2014;383:963–9. [DOI] [PubMed] [Google Scholar]
- 6.Lindeman JH, Matsumura JS. Pharmacologic management of aneurysms. Circ Res. 2019;124:631–46. 10.1161/CIRCRESAHA.118.312439 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Braverman AC. Medical management of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg. 2013;145:S2–6. 10.1016/j.jtcvs.2012.11.062 [DOI] [PubMed] [Google Scholar]
- 8.Jambusaria A, Hong Z, Zhang L, Srivastava S, Jana A, Toth PT, et al. Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation. Elife. 2020;9:e51413. 10.7554/eLife.51413 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cho JG, Lee A, Chang W, Lee MS, Kim J. Endothelial to mesenchymal transition represents a key link in the interaction between inflammation and endothelial dysfunction. Front Immunol. 2018;9:294. 10.3389/fimmu.2018.00294 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Yuan Z, Lu Y, Wei J, Wu J, Yang J, Cai Z. Abdominal aortic aneurysm: roles of inflammatory cells. Front Immunol. 2021;11:609161. 10.3389/fimmu.2020.609161 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chen PY, Schwartz MA, Simons M. Endothelial-to-mesenchymal transition, vascular inflammation, and atherosclerosis. Front Cardiovasc Med. 2020;7:53. 10.3389/fcvm.2020.00053 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Souilhol C, Harmsen MC, Evans PC, Krenning G. Endothelial-mesenchymal transition in atherosclerosis. Cardiovasc Res. 2018;114:565–77. 10.1093/cvr/cvx253 [DOI] [PubMed] [Google Scholar]
- 13.Maleszewska M, Moonen JRAJ, Huijkman N, van de Sluis B, Krenning G, Harmsen MC. IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner. Immunobiology. 2013;218: 443–54. 10.1016/j.imbio.2012.05.026 [DOI] [PubMed] [Google Scholar]
- 14.Johnston WF, Salmon M, Su G, Lu G, Stone ML, Zhao Y, et al. Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2013;33:294–304. 10.1161/ATVBAHA.112.300432 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Johnston WF, Salmon M, Pope NH, Meher A, Su G, Stone ML, et al. Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms. Circulation. 2014;130:S51–9. 10.1161/CIRCULATIONAHA.113.006800 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bhamidipati CM, Mehta GS, Lu G, Moehle CW, Barbery C, DiMusto PD, et al. Development of a novel murine model of aortic aneurysms using peri-adventitial elastase. Surgery (United States). 2012;152:238–46. 10.1016/j.surg.2012.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature. 2009;457:887–91. 10.1038/nature07619 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Pinteaux E, Abdulaal WH, Mufazalov IA, Humphreys NE, Simonsen-Jackson M, Francis S, et al. Cell-specific conditional deletion of interleukin-1 (IL-1) ligands and its receptors: a new toolbox to study the role of IL-1 in health and disease. J Mol Med (Berl). 2020;98:923–30. 10.1007/s00109-020-01928-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Bankhead P, Loughrey MB, Fernández JA, McArt DG, Dunne PD, McQuaid S, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878. 10.1038/s41598-017-17204-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ippolito C, Colucci R, Segnani C, Errede M, Girolamo F, Virgintino D, et al. Fibrotic and vascular remodelling of colonic wall in patients with active ulcerative colitis. J Crohns Colitis. 2016;10:1194–204. 10.1093/eccojcc/jjw076 [DOI] [PubMed] [Google Scholar]
- 21.Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J. The role of interleukin-1 in general pathology. Inflamm Regen. 2019;39:12. 10.1186/s41232-019-0101-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7:re8. 10.1126/scisignal.2005189 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Piera-Velazquez S, Jimenez SA. Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases. Physiol Rev. 2019;99:1281–324. 10.1152/physrev.00021.2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Pérez L, Muñoz-Durango N, Riedel CA, Echeverría C, Kalergis AM, Cabello-Verrugio C, et al. Endothelial-to-mesenchymal transition: cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev. 2017;33:41–54. 10.1016/j.cytogfr.2016.09.002 [DOI] [PubMed] [Google Scholar]
- 25.Katsuno Y, Derynck R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family. Dev Cell. 2021;56:726–46. 10.1016/j.devcel.2021.02.028 [DOI] [PubMed] [Google Scholar]
- 26.Jia W, Wang Z, Gao C, Wu J, Wu Q. Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis. Cell Death Dis. 2021;12:327. 10.1038/s41419-021-03603-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Peiró C, Lorenzo O, Carraro R, Sánchez-Ferrer CF. IL-1β inhibition in cardiovascular complications associated to diabetes mellitus. Front Pharmacol. 2017;8:363. 10.3389/fphar.2017.00363 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50. 10.1146/annurev.immunol.021908.132612 [DOI] [PubMed] [Google Scholar]
- 29.Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173:57–67. 10.2353/ajpath.2008.070974 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009;57:165–76. 10.1007/s00005-009-0024-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Gomez D, Baylis RA, Durgin BG, Newman AAC, Alencar GF, Mahan S, et al. Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat Med. 2018;24:1418–29. 10.1038/s41591-018-0124-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Da Ros F, Carnevale R, Cifelli G, Bizzotto D, Casaburo M, Perrotta M, et al. Targeting interleukin-1β protects from aortic aneurysms induced by disrupted transforming growth factor b signaling. Immunity. 2017;47:959–73.e9. 10.1016/j.immuni.2017.10.016 [DOI] [PubMed] [Google Scholar]
- 33.Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720–32. 10.1182/blood-2010-07-273417 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Abbate A, Trankle CR, Buckley LF, Appleton D, Kadariya D, Canada JM, et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with st-segment–elevation myocardial infarction. J Am Heart Assoc. 2020;9:e014941. 10.1161/JAHA.119.014941 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Pope NH, Salmon M, Johnston WF, Lu G, Lau CL, Upchurch GR, et al. Interleukin-6 receptor inhibition prevents descending thoracic aortic aneurysm formation. Ann Thorac Surg. 2015;100:1620–6. 10.1016/j.athoracsur.2015.05.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sinha S, Iyer D, Granata A. Embryonic origins of human vascular smooth muscle cells: implications for in vitro modeling and clinical application. Cell Mol Life Sci. 2014;71:2271–88. 10.1007/s00018-013-1554-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Ruddy JM, Jones JA, Spinale FG, Ikonomidis JS. Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg. 2008;136:1123–30. 10.1016/j.jtcvs.2008.06.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.van de Pol V, Kurakula K, DeRuiter MC, Goumans MJ. Thoracic aortic aneurysm development in patients with bicuspid aortic valve: what is the role of endothelial cells? Front Physiol. 2017;8:938. 10.3389/fphys.2017.00938 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Maleki S, Poujade FA, Bergman O, Gådin JR, Simon N, Lång K, et al. Endothelial/epithelial mesenchymal transition in ascending aortas of patients with bicuspid aortic valve. Front Cardiovasc Med. 2019;6:182. 10.3389/fcvm.2019.00182 [DOI] [PMC free article] [PubMed] [Google Scholar]
